Fig. 2: Characterization of formulations.

a Schematic compositions and self-assembly of DMS. b Corresponding sizes and PDIs of DMS prepared from different concentrations of AG17724 and cholesterol materials. Three independent repetitions got similar results. c Validation of DNA barcodes on DMS via using fluorescent probe-labeled complimentary DNA oligos. I, DMS; II, DMS-Cy5/Cy3.5/A488; III, DMS incubated with Cy5-scrambled DNA, Cy3.5-scrambled DNA, and A488-scrambled DNA. Three independent repetitions got similar results. d Schematic workflow to prepare antiCAFs-DMS and antiCAFs-DMS-AptT from DMS. e Hydrodynamic size distributions of DMS, antiCAFs-DMS, and antiCAFs-DMS-AptT. Three independent repetitions got similar results. f TEM images of nanoparticles. Scale bars are 100 nm. Three independent repetitions got similar results. g Silver staining-based antibody detections after releasing antibodies from the nanoparticles. Three independent repetitions got similar results. Source data are provided as a Source Data file.